title: Natalizumab risk stratification: role of a two- step anti-JCV antibody assay.
authors.affiliation: Department of Neurology, St. Michael's Hospital, Toronto, Ontario, Canada.
authors.forename: Paul W
authors.initials: PW
authors.lastname: O'Connor
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D007577:JC Virus / Q000276:immunology*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000097:blood / Q000175:diagnosis* / Q000209:etiology*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy; D000069442:Natalizumab; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069442:Natalizumab